THE ROLE OF RECOMBINANT HUMAN FUSION PROTEIN IL－6／IL－2（CH925） IN HEPADNA VIRUS INFECTION TREATMENT

ＴＨＥＲＯＬＥＯＦＲＥＣＯＭＢＩＮＡＮＴＨＵＭＡＮＦＵＳＩＯＮＰＲＯＴＥＩＮＩＬ－６／ＩＬ－２（ＣＨ９２５）ＩＮＨＥＰＡＤＮＡＶＩＲＵＳＩＮＦＥＣＴＩＯＮＴＲＥＡＴＭＥＮＴＭｉＺｈｉｂａｏ（米志宝），ＺｈａｏＣｈｕｎｈｕａ（赵春华），ＺｈａｎｇＸｉｔ...

THE ROLE OF RECOMBINANT HUMAN FUSION PROTEIN IL- 6/IL-2 (CH925 ) IN HEPADNA VIRUS INFECTION TREATMENT

The effects of CH925, a novel immune modulator, on hepadna virus infection was evaluated. Day-old ducklings were inoculated intravenously with LJ-76 DHBV containing serum. Infected ducklings were then treated with the CH925 and the mixture of IL-2 and IL-6 intravenously and the control ducklings received equivalent normal saline (NS). Blood and liver samples were taken and assayed for DHBV DNA and /or DHBsAg. At the completion of the experiment there was a inhibition of viremia with the CH925 and IL-2 IL-6. Serum DHBV DNA was detected in 6 of 10 ducks in 100 000 unit/kg dosage group, 7 of 10 ducks in 50 000 unit/kg dosage group and 6 of 10 ducks in IL-2 IL-6 dosage group, compared with 9 of 10 NS control, and it showed a similar result in circulating DHBsAg. When samples of liver DNA were processed for hybridization, a little difference in the DHBV DNA replication was noted between ducks receiving CH925, IL-2 IL-6 or NS placebo. It is suggested that CH925 might be a potential remedy in HBV infection treatment.